El Rubius

Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies

Retrieved on: 
Wednesday, November 15, 2023

DUBLIN, Ireland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) today launched as an independent, publicly traded, clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Mural’s ordinary shares will begin trading on the Nasdaq Global Market tomorrow, November 16th, under the ticker symbol “MURA”.

Key Points: 
  • “Immunotherapies have made a tremendous impact on the treatment of cancers over the past decade,” said Caroline Loew, Ph.D., the Company’s chief executive officer.
  • We believe Mural Oncology can lead the future of immunotherapies for patients.
  • Our protein engineering expertise allows us to reimagine the development of pro-inflammatory cytokine-based therapeutics that could address the key limitations with current cancer immunotherapies.
  • Goodwin Procter LLP and Arthur Cox LLP are serving as legal counsel to Mural Oncology.

Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role

Retrieved on: 
Monday, May 8, 2023

Incyte (Nasdaq:INCY) today announced the creation of a new leadership role, appointing Pablo J. Cagnoni, M.D.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced the creation of a new leadership role, appointing Pablo J. Cagnoni, M.D.
  • President and Head of Research & Development (R&D) effective June 5, 2023.
  • “This newly created role integrates chemistry, biology and development with the goal of maximizing the impact of our portfolio and accelerating our innovative pipeline,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
  • “Incyte has a strong foundation of bringing first-in-class treatments to patients and I am honored to join the organization,” said Dr. Cagnoni.

ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer

Retrieved on: 
Monday, December 19, 2022

ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022.

Key Points: 
  • ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022.
  • As we enter the next phase of growth, I am confident that his extensive financial background, deep capital markets experience and proven leadership in the pharmaceutical industry will help drive our corporate objectives and deliver long-term value for shareholders,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.
  • He most recently served as CFO of Rubius Therapeutics where he was responsible for all financial functions as well as business development, investor relations, information technology and procurement.
  • “I am thrilled to join ADC Therapeutics, especially at this exciting point in the Company’s evolution,” said Mr. Carmona.

Laronde Appoints Pablo J. Cagnoni as Chief Executive Officer

Retrieved on: 
Thursday, November 17, 2022

Laronde is an exceptional company built on a truly unique platform with the potential to change the way we approach medicine, said Pablo J. Cagnoni, MD, Chief Executive Officer, Laronde and Executive Partner, Flagship Pioneering.

Key Points: 
  • Laronde is an exceptional company built on a truly unique platform with the potential to change the way we approach medicine, said Pablo J. Cagnoni, MD, Chief Executive Officer, Laronde and Executive Partner, Flagship Pioneering.
  • Dr. Cagnoni most recently served as President and Chief Executive Officer of Rubius Therapeutics.
  • Before joining Rubius in 2018, Dr. Cagnoni served as President and Chief Executive Officer of Tizona Therapeutics, a privately held biotech company focused on developing next generation immunotherapies for the treatment of cancer.
  • From 2007 to 2009, Dr. Cagnoni was Senior Vice President and Chief Medical Officer at Allos Therapeutics (acquired by Spectrum Pharmaceuticals) and, prior to that, Chief Medical Officer of OSI Pharmaceuticals (acquired by Astellas).

Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes

Retrieved on: 
Wednesday, November 2, 2022

CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and plans to engage an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of the Company or a merger. As a result of this process, Rubius is reducing its workforce by 84% and will retain certain employees to execute the process. The Company also announced the appointment of Dannielle Appelhans as president and chief executive officer, effective November 15, 2022. Ms. Appelhans previously served as chief operating officer since joining Rubius in 2021. Current president and chief executive officer, Pablo J. Cagnoni, M.D., was appointed Chair of the Rubius board of directors, effective immediately, and will continue as president and chief executive officer until November 15, 2022.

Key Points: 
  • Strategic alternatives that will be evaluated include the sale of all or part of the Company or a merger.
  • As a result of this process, Rubius is reducing its workforce by 84% and will retain certain employees to execute the process.
  • Additional leadership changes include the departures of Pepe Carmona, chief financial officer, and Maiken Keson-Brookes, chief legal officer and corporate secretary.
  • Rubius Therapeutics is a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases.

Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

Retrieved on: 
Monday, September 19, 2022

A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website.

Key Points: 
  • A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website.
  • An archived replay will be accessible for 90 days following the event.
  • Rubius Therapeutics is a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases.
  • We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Rubius Therapeutics Announces Strategic Update

Retrieved on: 
Tuesday, September 13, 2022

CAMBRIDGE, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to restructure the Company and align resources to advance its next generation red blood cell-based cell conjugation platform.

Key Points: 
  • With more than 80 patients dosed across three clinical trials to date, Rubius Therapeutics has demonstrated that engineered red blood cells can be manufactured at scale, safely administered and activate a patients immune system, resulting in clinical benefit in certain cancer patients, including evidence of tumor shrinkage and prolonged stable disease in PD-(L)-1 refractory solid tumors, said Pablo J. Cagnoni, M.D., president and chief executive officer of Rubius Therapeutics.
  • Based on these early findings, we firmly believe in the potential of Red Cell Therapeutics for the treatment of cancer and autoimmunity.
  • An audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website and can be directly accessed here .
  • Rubius Therapeutics is a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases.

Rubius Therapeutics to Provide Strategic Update

Retrieved on: 
Monday, September 12, 2022

CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced that the Company plans to provide a strategic update and host an investor teleconference and webcast on Tuesday, September 13, 2022, at 7:30 a.m. EDT.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced that the Company plans to provide a strategic update and host an investor teleconference and webcast on Tuesday, September 13, 2022, at 7:30 a.m. EDT.
  • An audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website and can be directly accessed here .
  • Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.
  • Rubius initial focus is to advance RCT product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities potent cell-cell interaction and tolerance induction.

Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 9, 2022

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today reported second quarter 2022 financial results and provided a business update.

Key Points: 
  • RTX-240 is designed to broadly stimulate the immune system by activating and expanding both NK and CD8+ memory T cells to generate an anti-tumor response.
  • Net loss for the second quarter of 2022 was $44.2 million or $0.49 per common share, compared to $50.2 million or $0.56 per common share in the second quarter of 2021.
  • In the second quarter of 2022, Rubius invested $33.0 million in research and development (R&D) related to its novel RED PLATFORM and towards expanding and advancing its product pipeline, as compared to $36.1 million in the second quarter of 2021.
  • G&A expenses were $9.9 million during the second quarter of 2022, as compared to $13.9 million for the second quarter of 2021.

Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors

Retrieved on: 
Thursday, July 14, 2022

Also, today, Rubius announced that Anne Prener, M.D., Ph.D., is stepping down from her role on the board of directors, effective today.

Key Points: 
  • Also, today, Rubius announced that Anne Prener, M.D., Ph.D., is stepping down from her role on the board of directors, effective today.
  • Susannes deep knowledge in oncology drug development and commercialization will be instrumental as we continue to advance our oncology pipeline of Red Cell Therapeutics, including RTX-240 and RTX-224 for the treatment of solid tumors.
  • I am thrilled to welcome Susanne to the Rubius board of directors, said Pablo J. Cagnoni, M.D., president and chief executive officer of Rubius Therapeutics.
  • Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.